1-20 of 63
Ping Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy

Guang-Tan Lin, Cheng Yan, Lu-Jie Li, Xiao-Wen Qiu, Yu-Xuan Zhao, Ju-Li Lin, Yu-Jing Chen, Chuan Feng, Shao-Qiong Chen, Jian-Wei Xie, Chao-Hui Zheng, Sachiyo Nomura, Chang-Ming Huang, Ping Li, Long-Long Cao
Journal: Cancer Research
Cancer Res (2025)
https://doi.org/10.1158/0008-5472.CAN-24-2697
Published: 07 March 2025
View article titled, Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Open the PDF for Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract PO1-07-04: Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer

Han Wang, Xiao-Hong Ding, Cheng-Lin Liu, Yi Xiao, Ruo-Hong Shui, Yan-Ping Li, Chen Chen, Wen-Tao Yang, Zhi-Ming Shao, Yi-Zhou Jiang
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-07-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-07-04
Published: 02 May 2024
View article titled, Abstract PO1-07-04: Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer
Journal Articles

Abstract PO1-13-01: Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study

Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Qiang Liu, Jifeng Feng, Hui-Ping Li, Xiaojia Wang, Ning Liao, Liu Yang, Qinyi Zhu, Chenxi Qian, Zefei Jiang
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-13-01.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-13-01
Published: 02 May 2024
View article titled, Abstract PO1-13-01: Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study
Journal Articles

Abstract PO2-27-11: Antitumor efficacy and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER+ and HER2+ metastatic breast cancer: A phase Ib study

Hui-Ping Li, Qingyuan Zhang, Ruyan Zhang, Yaxin Liu, Chang Liu, Xianjun Hu
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-27-11.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-27-11
Published: 02 May 2024
View article titled, Abstract PO2-27-11: Antitumor efficacy and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER+ and HER2+ metastatic breast cancer: A phase Ib study
Journal Articles

Abstract PO2-05-13: HER2 status presented an unstable switching from primary to recurrent breast cancer

Anjie Zhu, Hui-Ping Li
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-05-13.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-05-13
Published: 02 May 2024
View article titled, Abstract PO2-05-13: HER2 status presented an unstable switching from primary to recurrent breast cancer
Journal Articles

Abstract PO4-04-02: Real-world first line use of trastuzumab biosimilar (HLX02), pertuzumab and chemotherapy for Chinese patients with HER2-positive metastatic breast cancer

Ruyan Zhang, Guohong Song, Xiaoran Liu, Hui-Ping Li
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-04-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-04-02
Published: 02 May 2024
View article titled, Abstract PO4-04-02: Real-world first line use of trastuzumab biosimilar (HLX02), pertuzumab and chemotherapy for Chinese patients with HER2-positive metastatic breast cancer
Journal Articles

Abstract PO4-04-01: Antitumor activity and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER and HER2 both positive metastatic breast cancer: A phase Ib study

Hui-Ping Li, Qingyuan Zhang, Ruyan Zhang, Yaxin Liu, Xianjun Hu
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-04-01.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-04-01
Published: 02 May 2024
View article titled, Abstract PO4-04-01: Antitumor activity and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER and HER2 both positive metastatic breast cancer: A phase Ib study
Journal Articles

Abstract PS15-07: Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study

Hui-Ping Li, Guohong Song, Hanfang Jiang, Xu Liang, Xiaojia Wang, Hua Yang, Lili Zhang, Youzhi Tong
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS15-07.
https://doi.org/10.1158/1538-7445.SABCS23-PS15-07
Published: 02 May 2024
View article titled, Abstract PS15-07: Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study
Journal Articles

Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer

Ru-Hong Tu, Sheng-Ze Wu, Ze-Ning Huang, Qing Zhong, Yin-Hua Ye, Chao-Hui Zheng, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Chang-Ming Huang, Mi Lin, Jun Lu, Long-Long Cao, Ping Li
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3868–3885.
https://doi.org/10.1158/0008-5472.CAN-23-1012
Published: 01 December 2023
View article titled, Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Open the PDF for Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

Yanke Liang, Mathew E. Sowa, Katrina L. Jackson, Jeffrey R. Simard, Bridget Kreger, Ping Li, Laura Poling, Joelle Baddour, Andrew Good, Hongwei Huang, Scott Eron, Christopher G. Nasveschuk, Robert Yu, Mark Fitzgerald, Victoria Garza, Morgan W. O’Shea, Gesine Veits, Jeremy L. Yap, Moses Moustakim, Ashley Hart, Roman V. Agafonov, Grace Sarkissian, Joe S. Patel, Richard Deibler, Kyle S. Cole, David Cocozziello, Fazlur Rahman, Andrew J. Phillips, Elizabeth Norton, Adam S. Crystal, Roy M. Pollock, Stewart L. Fisher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): ND05.
https://doi.org/10.1158/1538-7445.AM2023-ND05
Published: 29 May 2023
View article titled, Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Journal Articles

Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

Yanke Liang, Mathew E. Sowa, Katrina L. Jackson, Jeffrey R. Simard, Bridget Kreger, Ping Li, Laura Poling, Joelle Baddour, Andrew Good, Hongwei Huang, Scott Eron, Christopher G. Nasveschuk, Robert Yu, Mark Fitzgerald, Victoria Garza, Morgan W. O’Shea, Gesine Veits, Jeremy Y. Yap, Moses Moustakim, Ashley Hart, Roman V. Agafonov, Grace Sarkissian, Joe S. Patel, Richard Deibler, Kyle S. Cole, David Cocozziello, Fazlur Rahman, Andrew J. Phillips, Elizabeth Norton, Adam S. Crystal, Roy M. Pollock, Stewart L. Fisher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3425.
https://doi.org/10.1158/1538-7445.AM2023-3425
Published: 04 April 2023
View article titled, Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Journal Articles

Abstract P4-01-43: PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

Xichun Hu, Jun Cao, Yue’e Teng, Hui-Ping Li, Lili Zhang, Quchang Ouyang, Weimin Xie, Yueyin Pan, Zhenchuan Song, Xiaoling Ling, Xiaohong Wu, Jingwei Xu, Li Li, Liping Ren, Hong Wang, Dongxian Zhou, Jing Luo
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-01-43.
https://doi.org/10.1158/1538-7445.SABCS22-P4-01-43
Published: 01 March 2023
View article titled, Abstract P4-01-43: PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial
Journal Articles

Abstract OT3-27-01: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial

Zhi-Ming Shao, Zhong-Hua Wang, Yi-Zhou Jiang, Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-27-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-27-01
Published: 01 March 2023
View article titled, Abstract OT3-27-01: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial
Journal Articles

CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma

Jingshu Xiao, Jiaming Liang, Junjie Fan, Panpan Hou, Xiaodong Li, Haipeng Zhang, Kai Li, Lang Bu, Ping Li, Miao He, Yongheng Zhong, Liping Guo, Penghui Jia, Qiaoqiao Xiao, Junyu Wu, Hong Peng, Chunmei Li, Fan Xing, Deyin Guo
Journal: Cancer Research
Cancer Res (2022) 82 (18): 3359–3374.
https://doi.org/10.1158/0008-5472.CAN-21-3656
Published: 16 September 2022
View article titled, CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma
Open the PDF for CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2435: EZH2 engages TGFb signaling to promote breast cancer bone metastasis via Integrin b1-FAK activation

Lin Zhang, Jingkun Qu, Yutao Qi, Yimin Duan, Yu-Wen Huang, Zhifen Zhou, Ping Li, Jun Yao, Beibei Huang, Shuxing Zhang, Dihua Yu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2435.
https://doi.org/10.1158/1538-7445.AM2022-2435
Published: 15 June 2022
View article titled, Abstract 2435: EZH2 engages TGFb signaling to promote breast cancer bone metastasis via Integrin b1-FAK activation
Journal Articles

Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Yingrui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Rui-Hua Xu, Coherus Biosciences and Shanghai Junshi Biosciences
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT226.
https://doi.org/10.1158/1538-7445.AM2022-CT226
Published: 15 June 2022
View article titled, Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
Journal Articles

Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers

Mathew E. Sowa, Bridget Kreger, Joelle Baddour, Yanke Liang, Jeffrey R. Simard, Laura Poling, Ping Li, Robert Yu, Ashley Hart, Roman V. Agafonov, Grace Sarkissian, Joe Sahil Patel, Richard Deibler, Kyle S. Cole, Scott Eron, David Cocozziello, Fazlur Rahman, Moses Moustakim, Christopher G. Nasveschuk, Katrina L. Jackson, Mark Fitzgerald, Victoria Garza, Morgan O’Shea, Gesine Veits, Jeremy L. Yap, Andrew J. Phillips, Elizabeth Norton, Adam S. Crystal, Stewart L. Fisher, Roy M. Pollock
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2158.
https://doi.org/10.1158/1538-7445.AM2022-2158
Published: 15 June 2022
View article titled, Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers
Journal Articles

Abstract 2592: Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer

Yuan Zhang, Jinyang Wang, Yi Xiao, Xiangliang Yuan, Ping Li, Yimin Duan, Victoria L. Seewaldt, Dihua Yu
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2592.
https://doi.org/10.1158/1538-7445.AM2021-2592
Published: 01 July 2021
View article titled, Abstract 2592: Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer
Journal Articles

Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300

Thomas K. Sin, Guohua Zhang, Zicheng Zhang, James Z. Zhu, Yan Zuo, Jeffrey A. Frost, Min Li, Yi-Ping Li
Journal: Cancer Research
Cancer Res (2021) 81 (4): 885–897.
https://doi.org/10.1158/0008-5472.CAN-19-3219
Published: 15 February 2021
View article titled, Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300
Open the PDF for Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300 in another window
Includes: Supplementary data
Journal Articles

Abstract 3079: FT-6876, a potent and selective inhibitor of CBP/p300 with antitumor activity in AR-positive breast cancer

Maureen Caligiuri, Grace L. Williams, Jennifer Castro, Linda Battalagine, Kristina Muskiewicz, Erik Wilker, Lili Yao, Shawn Schiller, Angela Toms, Ping Li, Eneida Pardo, Bradford Graves, Kenneth W. Wood, Sylvie M. Guichard
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3079.
https://doi.org/10.1158/1538-7445.AM2020-3079
Published: 15 August 2020
View article titled, Abstract 3079: FT-6876, a potent and selective inhibitor of CBP/p300 with antitumor activity in AR-positive breast cancer